The estimated Net Worth of Llcfil Ltd Fmr is at least $22.9 Миллион dollars as of 28 March 2013. Llcfil Fmr owns over 158,068 units of Ironwood Pharmaceuticals Inc stock worth over $3,644,152 and over the last 13 years Llcfil sold IRWD stock worth over $19,279,456.
Llcfil has made over 16 trades of the Ironwood Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Llcfil sold 158,068 units of IRWD stock worth $2,908,451 on 28 March 2013.
The largest trade Llcfil's ever made was selling 235,686 units of Ironwood Pharmaceuticals Inc stock on 21 September 2012 worth over $3,408,020. On average, Llcfil trades about 71,791 units every 14 days since 2012. As of 28 March 2013 Llcfil still owns at least 837,736 units of Ironwood Pharmaceuticals Inc stock.
You can see the complete history of Llcfil Fmr stock trades at the bottom of the page.
Llcfil's mailing address filed with the SEC is 82 DEVONSHIRE STREETP.O. BOX H.M. 670, , BOSTONHAMILTON, MAD0, 0210900000.
Over the last 15 years, insiders at Ironwood Pharmaceuticals Inc have traded over $83,928,361 worth of Ironwood Pharmaceuticals Inc stock and bought 2,478,676 units worth $24,100,589 . The most active insiders traders include Llc Fmr, Bryan E Roberts и Alexander J Denner. On average, Ironwood Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of $239,611. The most recent stock trade was executed by Minardo John on 12 August 2024, trading 9,910 units of IRWD stock currently worth $42,316.
ironwood pharmaceuticals (nasdaq: irwd) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. we discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (ibs-c) or chronic idiopathic constipation (cic). we are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. ironwood was founded in 1998 out of the whitehead institute for b
Ironwood Pharmaceuticals Inc executives and other stock owners filed with the SEC include: